



Pixium Vision welcomed French Health Minister, Marisol Touraine at the « Institut de la Vision » in Paris

During her visit, the Minister for Social Affairs, Health and Women's Rights was able to learn more about the progress made by Pixium Vision in the development of its vision restoration systems

Paris, 22 April 2015 - Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, today announced that it received the visit from Marisol Touraine, Minister for Social Affairs, Health and Women's Rights.

Pixium Vision is currently conducting clinical trials in the development of IRIS[®], its first vision restoration system. This system is designed for patients blinded by Retinitis Pigmentosa (RP), an irreversible condition for which there is no current cure, affecting more than one and a half million people worldwide.

During her visit, Marisol Touraine met one of the patients using the IRIS[®] system. Having become blind more than twenty years ago, he is now able to move around more independently and distinguish shapes and objects.

Marisol Touraine welcomed the innovation delivered by the IRIS[®] system: a significant step forward and an innovative technology, meeting substantial social and clinical needs for patients suffering from this highly debilitating condition.

Khalid Ishaque, CEO of Pixium Vision added, *"Pixium Vision is the only company developing two different approaches to stimulate the retina. We will commercialise our first system, IRIS[®], after approval expected towards the end of 2015. We will also initiate clinical trials of our second system in 2016, a wireless, photovoltaic sub-retinal implant called PRIMA for which highly encouraging preclinical results were announced earlier today."* **Khalid Ishaque** concluded: *"Pixium Vision will closely follow the measures that will be implemented to support research and innovation in healthcare."*

Contacts

Pixium Vision

Pierre Kemula, CFO

investors@pixium-vision.com

+33 1 76 21 47 30

 @PixiumVision

Investor Relations

Citigate Dewe Rogerson

Lucie Larguier – Laurence Bault

pixium-vision@citigate.fr

+33 1 53 32 84 78

Press Relations

Newcap Media

Annie-Florence Loyer

Nadège Le Lezec

afloyer@newcap.fr

nlelezec@newcap.fr

About Pixium Vision (www.pixium-vision.com, @PixiumVision)

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. The Company harnesses the rapid advances in visual processing, microelectronics / nanoelectronics, optoelectronics, neurobiology and intelligent software algorithms. Pixium Vision's VRS are associated with a surgical intervention as well as a rehabilitation period.

Clinical trials are currently underway with the VRS IRIS[®] in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. The results of these studies will be used to apply for CE mark. The approval of IRIS[®] is expected in 2015.

Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.



Pixium Vision is listed on Euronext (Compartment C) in Paris.

ISIN: FR0011950641; Mnemo: PIX

IRIS[®] is a trademark of Pixium-Vision SA

Disclaimer

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Documents de Base filed with the AMF under number I. 14-030 on May 12, 2014 and Chapter 2 "Risk Factors related to the Offer" in the prospectus, which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).